Two possible cases of erenumab-induced xerostomia

J Clin Pharm Ther. 2022 Jun;47(6):824-825. doi: 10.1111/jcpt.13595. Epub 2021 Dec 22.

Abstract

What is known and objective: Erenumab is a monoclonal antibody for the prophylactic treatment of migraine. We describe the first cases of xerostomia probably induced by this drug.

Case summary: We present two patients diagnosed with chronic migraine who started treatment with erenumab and presented with dry mouth after the first and second dose.

What is new and conclusion: Xerostomia is not described as an adverse reaction in the drug's technical datasheet. A search was made in PubMed including 'erenumab', 'fremanezumab', 'galcanezumab', 'xerostomia', and no results were found. It is necessary to identify this potential adverse reaction in order to estimate its prevalence and possible impact on patients' quality of life.

Keywords: adverse; dry; erenumab; migraine; xerostomia.

Publication types

  • Case Reports

MeSH terms

  • Antibodies, Monoclonal, Humanized
  • Calcitonin Gene-Related Peptide Receptor Antagonists / adverse effects
  • Humans
  • Migraine Disorders* / drug therapy
  • Migraine Disorders* / prevention & control
  • Quality of Life
  • Xerostomia* / chemically induced

Substances

  • Antibodies, Monoclonal, Humanized
  • Calcitonin Gene-Related Peptide Receptor Antagonists
  • erenumab